Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
- Resource Type
- Editorial & Opinion
- Authors
- Kittai AS; Division of Hematology, The Ohio State University, Columbus, Ohio, USA.; Hang Y; Division of Hematology, The Ohio State University, Columbus, Ohio, USA.; Bhat SA; Division of Hematology, The Ohio State University, Columbus, Ohio, USA.; Clark A; US Medical Affairs, AstraZeneca Pharmaceuticals, Gaithersburg, Maryland, USA.; Grever M; Division of Hematology, The Ohio State University, Columbus, Ohio, USA.; Rhodes JM; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.; Roberts M; US Medical Affairs, AstraZeneca Pharmaceuticals, Gaithersburg, Maryland, USA.; Rogers KA; Division of Hematology, The Ohio State University, Columbus, Ohio, USA.; Teschemaker A; Global Evidence Generation, AstraZeneca Pharmaceuticals, Gaithersburg, Maryland, USA.; Munoz-Sagastibelza M; US Medical Affairs, AstraZeneca Pharmaceuticals, Gaithersburg, Maryland, USA.; Woyach JA; Division of Hematology, The Ohio State University, Columbus, Ohio, USA.; Barrientos JC; Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, USA.; Mount Sinai Comprehensive Cancer Center, Miami, Florida, USA.
- Source
- Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE
- Subject
- Language
- English
Kaplan-Meier curve depicting overall survival from CLL treatment start by race. For patients with CLL, no overall survival difference was observed between races in this real-world US database.
(© 2024 Wiley Periodicals LLC.)